The Acheivement’s of Proove Bio

News and Media

A medical test that aims to wean America off painkillers

The headlines about Prince's reported painkiller addiction have captured the nation's attention, but the stats on America's opioid crisis show that it's in no way surprising. Opioid addiction claimed 28,000 deaths in 2014, half from painkiller prescriptions, the...

May 5, 2016 – Proove Release: Proove Acquires Algynomics Founded by Leading Researchers in the Field of Pain Genetics

Proove Biosciences Closes on the Acquisition of Pain Genetics Firm Algynomics Proove Biosciences, Inc. today announced it has closed on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics company. The Algynomics platform and its patient...

December 7, 2016 – Proove Release: Proove Launches First Precision Medicine Test for TMJ Disorder

Proove Launches the Only Commercially Available Genetic Analysis Offering Personalized Medical Treatment Recommendations for TMD Sufferers and Insights Into Contributing Causes of Orofacial Pain IRVINE, CA--(Marketwired - Dec 7, 2016) - Proove Biosciences, Inc., the...

April 19, 2017 – Proove Release: First Published Study of Precision Medicine to Predict Opioid Abuse

Results Published in the Journal Pharmacogenomics and Personalized Medicine Shows Proove Opioid Risk® Accurately Identifies Prescription Opioid Abuse Risk IRVINE, Calif., April 19, 2017 /PRNewswire/ -- As a Bronze Sponsor of the National Rx Drug Abuse and Heroin...

May 2, 2017 – Proove Release: Proove CEO to Speak at 5 th Annual Medical Device Forum

Award-Winning Entrepreneur Brian Meshkin will speak at the 10X Medical Device Conference in San Diego IRVINE, Calif., May 2, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its founder and Chief Executive Officer, Brian Meshkin, will speak at the...

April 25, 2017 – Proove Release: Milestone of the World’s Largest Biobank and Big Data Set in Chronic Pain –

Proove® Announces Huge Milestone for its Proove Nexus™ Big Data Platform Commemorating National DNA Day IRVINE, Calif., April 25, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its Proove Nexus™ platform is the World's Largest DNA Pain Biobank and Big...

May 31, 2017 – Proove Release: Preliminary Results from Large Clinical Utility Study of Over 27,000 Patients Shows 90% of Patients Experience Significant Pain Reduction From Decisions Made with Proove Technology

Preliminary Results of 27,659 patients from MOSAIC Trial Demonstrate that Proove® Technology Leads to Better Patient Outcomes IRVINE, Calif., May 31, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces preliminary results at the close of a large patient-centered...

October 23, 2015 – Proove Release: Proove Partners with USC to Conduct Research

Proove Biosciences, a commercial and research leader in personalized medicine, is excited to announce their partnership with the Keck Medicine of the University of Southern California(USC) Pain Center to study the genetics of chronic pain. The T.R.O.J.A.N. Study...

March 16, 2017 – Proove Release: Key Opinion Leaders Present Precision Medicine Research from Proove at American Academy of Pain Medicine Meeting

Proove continues its leadership of precision pain medicine presenting over 100 studies at major medical meetings outlining breakthrough precision medicine research over the past 5 years IRVINE, Calif., March 16, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. is...

April 23, 2015 – Proove Release: Proove Biosciences Launches World's First Test To Predict Responders To Commonly Prescribed Non-Opioid Pain Medications

The new Proove Non-Opioid Pain Medication Response profile evaluates genetic factors to predict a patient’s response to non opioids before prescribing Irvine, CA (PRWEB) - Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to...

April 13, 2016 – Proove Release: Proove and Insurer Specialty Health Announce Positive Coverage Determination for Genetic Testing

IRVINE, CA and RENO, NV (PRWEB) April 13, 2016 Proove Biosciences and Specialty Health are excited to announce a positive policy decision on the use of Proove Genetic testing to achieve the quadruple aim of improving outcomes, reducing costs, improving patient care,...

Video’s

A medical test that aims to wean America off painkillers

The headlines about Prince's reported painkiller addiction have captured the nation's attention, but the stats on America's opioid crisis show that it's in no way surprising. Opioid addiction claimed 28,000 deaths in 2014, half from painkiller prescriptions, the...

Get Instant Access to Updates to The Truth about Proove Bio